RSK Inhibitor Crystal Forms for Stability and Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for small molecule inhibitors of RSK to treat various types of cancers, particularly triple-negative breast cancer, which is aggressive and has poor patient outcomes, as existing treatments often face drug resistance and genetic diversity.
Innovation Solution
Development of crystalline forms of (R)-N-(1-(4-aminobenzyl)-1H-pyrazol-4-yl)-9-methyl-6-oxo-6,7,8,9-tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-a]pyrazine-2-carboxamide hydrochloride, which acts as an RSK inhibitor, with specific properties defined by X-ray powder diffraction patterns, thermogravimetric analysis, and differential scanning calorimetry profiles, to enhance therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional RSK inhibitors are used to treat cancer, then therapeutic activity is achieved, but drug resistance develops and treatment effectiveness decreases
Solution Approach 1:
The patent applies parameter changes by developing multiple crystalline forms (polymorphs) of the RSK inhibitor with different physical properties. Different crystalline forms can exhibit varying solubility, dissolution rates, and stability characteristics, allowing optimization of therapeutic parameters to overcome drug resistance mechanisms while maintaining inhibitory activity against RSK enzymes.
Solution Approach 2:
The patent utilizes composite material principles by creating crystalline forms that may incorporate solvent molecules or form complexes with specific properties. These crystalline forms can be viewed as composite structures where the inhibitor molecules are arranged in specific crystal lattices, potentially enhancing therapeutic efficacy and reducing drug resistance.
2Adaptability or versatility
If RSK inhibitors are developed to address cancer genetic diversity, then treatment versatility improves, but formulation complexity increases
Solution Approach 1:
The patent applies universality by developing crystalline forms of a single RSK inhibitor compound that can be used across multiple cancer types and patient populations. The different crystalline forms provide a platform for universal application in treating various cancers (breast, prostate, lung, etc.) while maintaining consistent inhibitory activity, thereby achieving multi-functionality without requiring multiple different drug compounds.
3Manufacturing precision
If crystalline forms with specific XRPD patterns are developed, then product identity and purity are improved, but manufacturing precision requirements increase
Solution Approach 1:
The patent applies parameter changes in the crystallization process by optimizing conditions such as temperature, pH, solvent composition, and cooling rates to obtain specific crystalline forms with desired XRPD patterns. By controlling these parameters, the manufacturing process can be standardized to produce consistent crystalline forms with reproducible physical properties, balancing precision requirements with manufacturability.
Data Source
AI summary
Described herein are crystalline forms of (R)-N-(1-(4-aminobenzyl)-1H-pyrazol-4 -yl)-9-methyl-6-oxo-6,7,8,9-tetrahydropyrido [3′,2′: 4,5]-pyrrolo [1,2-a]pyrazine-2-carboxamide hydrochloride and solvates thereof; pharmaceutical compositions and use thereof in treating cancer such as breast cancer, prostate cancer, lung cancer, brain cancer, skin cancer, bone cancer, ovarian cancer, multiple myeloma and leukemia. Compound (I).